Shares of biotechnology company bluebird bio (NASDAQ:BLUE) slumped on Monday even as the company submitted its Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) gene therapy for the treatment of sickle cell disease patients with a history of vasoocclusive events.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The BLA submission is based on efficacy results in multiple patient groups and also includes safety data from 50 patients.
The application also includes a Priority Review request. If the priority review is granted, the review process for lovo-cel could be shortened to six months. Moreover, if approved, the therapy would become BLUE’s third ex-vivo gene therapy on the market for a rare genetic disease.
Sickle cell disease impacts nearly 100,000 people in the U.S. with half the people not living past 40 years of age. Overall, the Street has a $6.67 consensus price target on BLUE, pointing to a 94.5% potential upside in the stock. That’s after a nearly 51% slide in the share price so far in 2023.
Read full Disclosure
